-
ABOUT USAffiliated to SSY Group Limited, Hebei Guangxiang Technology Co., Ltd., is a high-tech enterprise specializing in drug research and technology development.
-
INNOVATIONSSY Group Limited has built a relatively perfect scientific research and innovation system with the synergy between “industry, academia, research and application” based on multi-disciplinary integration and multi-directional combination.
-
SUBORDINATEThe group has decided to establish research institutes in its subsidiaries, Hebei Ghuangxiang Drug Research Institute, Jiangsu Best Medical Material Research Institute, and Hebei Hanlin Biological Research Institute.
-
RECRUITWe actively establish a joint talent cultivation mechanism between schools and enterprises, and currently have over 500 high-level talents in various fields such as drug research, analysis, and clinical practice.
-
CONTACTWe will continue to strengthen innovation-driven development, vigorously promote the integration of production and research, constantly improve the five domains: new drugs, biological drugs, traditional Chinese medicine, generic drugs and APIs.
Shijiazhuang Sihua Pharmaceutical Group’s new product, Cinacalcet Hydrochloride Tablets, has been approved.
Category:
Time：2023-05-17
On May 17, the Class 4 chemical drug—Cinacalcet Hydrochloride Tablets (25mg)—submitted by Shijiazhuang Sihua Pharmaceutical Group obtained the drug production registration approval from the National Medical Products Administration and is deemed to have passed the consistency evaluation.
On May 17, the Class 4 chemical drug Sinacalcet Hydrochloride Tablets (25mg), submitted by Shijiazhuang Fourth Pharmaceutical Group, received the Drug Production Registration Approval from the National Medical Products Administration and is deemed to have passed the consistency evaluation.
It is reported that Cinacalcet Hydrochloride Tablets are primarily used to treat secondary hyperparathyroidism in patients with chronic kidney disease (CKD) undergoing maintenance dialysis.
Over the past two years, Shijiazhuang No.4 Pharmaceutical has been driven by innovation to promote high-quality enterprise development, and its R&D innovation efforts have entered a period of intensive harvest. As of now, the company has already obtained 27 new products this year, and its R&D efficiency continues to remain among the industry leaders nationwide. It is projected that more than 80 new products will be approved by the end of the year.
Meanwhile, the cumulative number of products that have passed the evaluation of generic drug quality and therapeutic equivalence (or are deemed to have passed such an evaluation) has reached 47 varieties and 61 specifications, continuously injecting new momentum into enterprises’ high-quality development.
Keywords:
Recommended News
Share to
SERVICE HOTLINE
Mobile site
E code
Business license